catalpol has been researched along with Kidney Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Huo, X; Liu, K; Ma, X; Meng, Q; Sun, H; Sun, P; Wang, C; Wu, J; Zhang, J; Zhao, T | 1 |
| Cao, Y; Chen, J; Ding, Y; Gao, Y; Lu, J; Lv, G; Peng, M; Sun, W; Sun, Y; Xu, H; Yu, B | 1 |
| Bi, R; Huo, X; Liu, K; Liu, Z; Ma, X; Meng, Q; Sun, H; Sun, P; Wang, C; Wu, J; Zhang, J | 1 |
3 other study(ies) available for catalpol and Kidney Diseases
| Article | Year |
|---|---|
Catalpol-Induced AMPK Activation Alleviates Cisplatin-Induced Nephrotoxicity through the Mitochondrial-Dependent Pathway without Compromising Its Anticancer Properties.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Cisplatin; Enzyme Activation; Iridoid Glucosides; Kidney Diseases; Male; Mice; Mitochondria | 2021 |
Catalpol ameliorates advanced glycation end product-induced dysfunction of glomerular endothelial cells via regulating nitric oxide synthesis by inducible nitric oxide synthase and endothelial nitric oxide synthase.
Topics: Animals; Chemokine CCL2; Endothelial Cells; Glycation End Products, Advanced; Humans; Intercellular Adhesion Molecule-1; Iridoid Glucosides; Kidney Diseases; Kidney Glomerulus; Macrophages; Mice; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases | 2019 |
Catalpol alleviates adriamycin-induced nephropathy by activating the SIRT1 signalling pathway in vivo and in vitro.
Topics: Acute Kidney Injury; Administration, Oral; Animals; Apoptosis; Cell Survival; Cells, Cultured; Doxorubicin; Iridoid Glucosides; Kidney Diseases; Male; Mice; Mice, Inbred Strains; Protective Agents; Rehmannia; Signal Transduction; Sirtuin 1 | 2019 |